Schizophrenia. N Engl J Med
2003; 349: 1738–49.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
McEvoy, JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psych
2006; 67: 15–8.
Janssen Pharmaceutica Products LP. Risperdal Consta (Risperidone) Long-Acting Injection Prescribing Information. Janssen Pharmaceutica Products LP, 2003.
Fang, J, Bourin, M, Baker, GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol
1999; 359: 147–51.
Nussbaum, AM, Stroup, TS. Oral paliperidone for schizophrenia. Cochrane Database Syst Rev
Janssen. Invega Sustenna (Paliperidone Palmitate) Extended-Release Injectable Suspension Prescribing Information. Orth-McNeil-Janssen Pharmaceuticals, 2009.
Nussbaum, AM, Stroup, TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev
Gopal, S, Hough, DW, Xu, H, Lull, JM, Gassmann-Mayer, C, Remmerie, BM, et al.
Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol
2010; 25: 247–56.
Hough, D, Gopal, S, Vijapurkar, U, Lim, P, Morozova, M, Eerdekens, M.
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res
2010; 116: 107–17.
Kramer, M, Litman, R, Hough, D, Lane, R, Lim, P, Liu, Y, et al.
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol
2009; 13: 635–47.
Nasrallah, HA, Gopal, S, Gassmann-Mayer, C, Quiroz, JA, Lim, P, Eerdekens, M, et al.
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacol
2010; 10: 2072–82.
Pandina, GJ, Lindenmayer, JP, Lull, J, Lim, P, Gopal, S, Herben, V, et al.
A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol
2010; 30: 235–44.
Fleischhacker, WW, Gopal, S, Lane, R, Gassmann-Mayer, C, Lim, P, Hough, D, et al.
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol
2011; Jul 22: 1–12. (Epub ahead of print.).
Pandina, G, Lane, R, Gopal, S, Gassmann-Mayer, C, Hough, D, Remmerie, B, et al.
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry
2011; 35: 218–26.
Nussbaum, AM, Stroup, TS. Paliperidone palmitate for schizophrenia. Schiz Bull
2012; 38: 1124–7.